Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-EHA 2026 Lymphoma
23 June 2026 | Virtual Meeting
Post-EHA 2026 Lymphoma Highlights
Featuring presentations & discussions on selected Lymphoma abstracts from the 31st Congress of the European Hematology Association (EHA).
Chair: Krish Patel | Moderators: Joanna Rhodes & Toby Eyre
The Post-EHA 2026 Lymphoma Highlights has been supported by AstraZeneca (Diamond Sponsor) and Genentech (Gold Sponsor). Supporters have no influence over the production of content.
Session 1: Advances in frontline therapy and risk-adapted management for LBCL & DLBCL
High-dose methotrexate does not reduce risk of CNS relapse in ultra high-risk large B-cell lymphoma: an international retrospective analysis of 1,923 patients
Matthew Wilson Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Epcoritamab + R-MINI-CHOP results in 2-year remissions and high MRD-negativity rates in elderly patients with newly diagnosed DLBCL: EPCORE NHL-2 trial
Chan Yoon Cheah Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia
Tafasitamab plus lenalidomide and R-CHOP for patients with previously untreated DLBCL: results from the Phase III FRONTMIND study
Umberto Vitolo Candiolo Cancer Institute, Turin, Italy
Panel Discussion
Session 2: Novel antibody-based approaches in R/R LBCL
Mosunetuzumab plus polatuzumab vedotin versus rituximab, gemcitabine and oxaliplatin in LBCL: updated efficacy and safety from the SUNMO study including in patient subgroups
Jason Westin The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Results from EPCORE DLBCL-1: randomized Phase III study of epcoritamab vs investigator’s choice chemoimmunotherapy in patients with R/R LBCL
Christopher Fox Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
Five-year follow-up of patients with R/R LBCL who achieved a complete response with glofitamab monotherapy
Krish Patel Sarah Cannon Research Institute, Nashville, TN, United States
Panel Discussion
Session 3: Recent progress in follicular lymphoma
Safety and efficacy of subcutaneous mosunetuzumab plus lenalidomide induction therapy followed by mosunetuzumab maintenance in previously untreated FL
Emmanuel Bachy Lyon Sud Hospital Center, Lyon, France
Phase III InMIND study of tafasitamab plus lenalidomide and rituximab for (R/R FL): outcomes in patients with or without high-risk factors
Paolo Strati The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Surovatamig (AZD0486) plus rituximab in previously untreated follicular lymphoma: initial safety data from the Phase III SOUNDTRACK-F1 trial
Chan Yoon Cheah Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia
Rituximab, golcadomide +/- nivolumab in treatment-naive follicular lymphoma: primary results of the investigator-led randomised Phase II TOP-FLOR study
Eliza Hawkes Olivia Newton-John Cancer Research Institute at Austin Health, Melbourne, Australia
Anchored matching-adjusted indirect comparison of epcoritamab, lenalidomide, and rituximab vs tafasitamab, lenalidomide, and rituximab in R/R FL: EPCORE FL-1 vs InMIND
Kim Linton University of Manchester, Manchester, United Kingdom
Panel discussion
